Adaptimmune Therapeutics (ADAP) Competitors $0.27 -0.01 (-2.85%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.28 +0.01 (+1.83%) As of 07/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADAP vs. CRVS, SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, ZYBT, CRDF, and MREOShould you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Corvus Pharmaceuticals (CRVS), Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Adaptimmune Therapeutics vs. Its Competitors Corvus Pharmaceuticals Sagimet Biosciences DBV Technologies Annexon Aerovate Therapeutics Allogene Therapeutics Tvardi Therapeutics Zhengye Biotechnology Cardiff Oncology Mereo BioPharma Group Corvus Pharmaceuticals (NASDAQ:CRVS) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings. Is CRVS or ADAP more profitable? Corvus Pharmaceuticals has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -38.91%. Corvus Pharmaceuticals' return on equity of -24.04% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -24.04% -13.90% Adaptimmune Therapeutics -38.91%-163.73%-23.65% Which has more risk & volatility, CRVS or ADAP? Corvus Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Do analysts rate CRVS or ADAP? Corvus Pharmaceuticals currently has a consensus price target of $15.00, suggesting a potential upside of 259.71%. Adaptimmune Therapeutics has a consensus price target of $1.35, suggesting a potential upside of 395.12%. Given Adaptimmune Therapeutics' higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Adaptimmune Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Does the media prefer CRVS or ADAP? In the previous week, Adaptimmune Therapeutics had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 2 mentions for Adaptimmune Therapeutics and 1 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.87 beat Adaptimmune Therapeutics' score of 0.87 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Corvus Pharmaceuticals Very Positive Adaptimmune Therapeutics Positive Do insiders and institutionals have more ownership in CRVS or ADAP? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by company insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation and earnings, CRVS or ADAP? Corvus Pharmaceuticals has higher earnings, but lower revenue than Adaptimmune Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$0.98-4.26Adaptimmune Therapeutics$179.64M0.40-$70.81M-$0.27-1.01 SummaryCorvus Pharmaceuticals beats Adaptimmune Therapeutics on 9 of the 15 factors compared between the two stocks. Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAP vs. The Competition Export to ExcelMetricAdaptimmune TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.48M$2.96B$5.62B$9.29BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-1.0120.2228.5719.58Price / Sales0.40290.24423.3293.40Price / CashN/A43.1536.0257.93Price / Book5.467.568.135.54Net Income-$70.81M-$55.11M$3.24B$257.73M7 Day Performance-1.02%3.81%0.16%-0.08%1 Month Performance7.40%11.60%5.95%8.09%1 Year Performance-78.50%-2.11%26.09%13.02% Adaptimmune Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAPAdaptimmune Therapeutics1.7931 of 5 stars$0.27-2.8%$1.35+395.1%-78.1%$74.48M$179.64M-1.01490CRVSCorvus Pharmaceuticals2.8458 of 5 stars$4.35+5.1%$15.00+244.8%+108.5%$296.54MN/A-4.4430Positive NewsSGMTSagimet Biosciences2.6329 of 5 stars$9.46-0.1%$26.60+181.2%+179.1%$290.14M$2M-5.388Positive NewsDBVTDBV Technologies3.9506 of 5 stars$10.58-2.1%$14.75+39.5%+157.2%$289.68M$4.15M-2.1580Gap UpANNXAnnexon2.5038 of 5 stars$2.61+1.2%$12.50+378.9%-59.5%$286.34MN/A-2.2160AVTEAerovate TherapeuticsN/A$9.82-6.7%N/A-86.5%$284.63MN/A-3.2820High Trading VolumeALLOAllogene Therapeutics3.6389 of 5 stars$1.29+0.8%$8.44+554.6%-58.4%$282.16M$20K-1.05310Positive NewsTVRDTvardi TherapeuticsN/A$29.83+9.1%$64.25+115.4%N/A$279.21M$7.14M0.0080News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeZYBTZhengye BiotechnologyN/A$5.87-0.3%N/AN/A$276.86M$186.36M0.00278Positive NewsGap UpCRDFCardiff Oncology1.2363 of 5 stars$4.13+1.5%$11.70+183.3%+64.1%$274.77M$680K-4.4920MREOMereo BioPharma Group1.5651 of 5 stars$1.72+6.8%$7.20+318.6%-58.8%$273.48M$10M-24.5740High Trading Volume Related Companies and Tools Related Companies CRVS Alternatives SGMT Alternatives DBVT Alternatives ANNX Alternatives AVTE Alternatives ALLO Alternatives TVRD Alternatives ZYBT Alternatives CRDF Alternatives MREO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADAP) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAP Stock Alerts